ArticleClinical rheumatology2017
Psoriatic arthritis: is it time to treat-to-target or target to treat?
Article in Clinical rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective.Rheumatology and therapy · 2023Article
- Consensus-based recommendations on the diagnosis, referral and clinical management of patients with psoriatic arthritis.Rheumatology international · 2022Review
- Article
- Role of comorbidities in spondyloarthritis including psoriatic arthritis.Clinical rheumatology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treat-to-target recommendations provide physicians a useful strategy to reduce the probability of disease progression and in general to manage PsA patients. However, it could be difficult to apply in real life, since PsA is a very heterogeneous disease with different manifestations to be treated. In fact, depending on the patient's expectation, some aspects of the disease could be prominent or not, beyond the mere achievement of the target of remission or low-disease activity. In this context, the concept of a "target to treat" strategy should be taken in to account.
Indexed as
Identifiers
29067586What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.